The Regorafenib Tablets Market continues to expand as targeted cancer therapies become increasingly important in modern oncology. Regorafenib is an oral multi-kinase inhibitor prescribed for the treatment of specific advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC). As cancer incidence rises globally and...